stock rating

Craig-Hallum sees substantial growth opportunity in Personalis' pharma partnerships and focus on underpenetrated cancer markets.

Craig-Hallum expects stable Prolaris revenues and sees opportunities for significant growth in the hereditary cancer and prenatal testing markets.

Craig-Hallum analyst Bill Bonello wrote that the investment bank expects the firm to return to year-over-year double-digit growth after a down year of single-digit growth.